Yakup Ergün: Metronomic Capecitabine Plus AI as Initial Therapy in HR+/HER2- mBC by Ruo-Xi Hong et al.
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X about a recent paper by Ruo-Xi Hong, physician at Sun Yat-Sen University Cancer Center, published in Journal of Clinical Oncology:
Authors: Ruo-Xi Hong, Fei Xu, Wen Xia, Jing-Min Zhang, Heng Huang et al.
“Metronomic Capecitabine Plus AI as Initial Therapy in Patients With HR+/HER2- mBC: MECCA Trial.
PFS – 20.9 vs 11.9 months
In regions where access to CDK4/6 inhibitors is limited, this could be an alternative option.
(The study was initiated in 2017, at which time palbociclib had already been approved by the FDA, but it likely had not yet been approved in China).”
Sarah Sammons, Breast Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared this post, adding:
“This trial challenges the paradigm that chemotherapy and endocrine therapy should not be administered concurrently in HR+ disease. Looking forward to some trial designs that challenge this concept further and are forthcoming.”
Sarah Sammons is a medical oncologist at Dana-Farber’s Breast Oncology Center specializing in treating patients with all stages of breast cancer. She is particularly focusing on improving outcomes for those with metastatic breast cancer. Through leading numerous clinical trials, she has developed new treatment options for breast cancer patients. Additionally, Dr. Sammons is skilled in treating brain metastases.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023